Approximately 20% of human breast cancers are characterized by overexpression of the HER2 receptor tyrosine kinase molecule. Multiple anitbodies have been designed to specifically target HER2, and each is able to target the molecule at a different epitope.
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses drug toxicity among targeted agents.
So far, there are no conclusive biomarkers to help identify subsets of patients who would benefit from antiangiogenic therapies, creating a barrier to the use of such treatments, Rugo said in her MBCC abstract.
Patients with ER-positive breast cancer, which accounts for approximately 70% of all cases, have benefited from the use of hormonal therapies to treat their disease.
Although targeted antibodies in cancer have been promising, most have only marginal activity in their targeted cancer and must be paired with a chemotherapeutic agent to maximize efficacy.
Gene expression profiling via the Oncotype DX 21-gene recurrence score assay has been used to assess risk and predict recurrence in hundreds of thousands of women over the course of nearly a decade.
The development of new drug combinations to treat patients with ER-negative breast cancer is being advanced by a growing understanding of the protein kinase activity along the EGFR pathway.
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the use of the reverse phase protein microarray (RPPA).
Fabrice André, MD, PhD, has focused his research on translational oncology and the development of novel targeted agents for the treatment of breast cancer through his research as director of INSERM Unit U981 at the Institut Gustave-Roussy in Villejuif, France.
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the Miami Breast Cancer Conference.
Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.
Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, discusses the use of pomalidomide in relapsed or refractory multiple myeloma.
Expanding the use of brentuximab vedotin to treat patients with advanced Hodgkin lymphoma and sALCL in earlier settings than currently indicated has resulted in high response rates in phase I studies.
Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, discusses CD30 as a target in lymphoma.
Quizartinib, a novel tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia in results of a phase II study presented during the 54th Annual ASH Meeting.
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses brentuximab vedotin in CD30-positive lymphomas.
An investigational, selective JAK2 inhibitor known as SAR302503 reduced spleen size in patients with myelofibrosis, according to phase II data presented at the 2012 American Society of Hematology Annual Meeting and Exposition.
Two studies presented at the 54th ASH Annual Meeting and Exposition, highlighted the possible use of panobinostat in combination with proteasome inhibitors for the treatment of relapsed or refractory multiple myeloma.
The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab, raising the prospect of a promising new therapy for elderly and frail patients who currently have few viable options.
Mark J. Levis, MD, PhD, discusses the design and results of a phase II trial of quizartinib in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.
Meletios A. Dimopoulos, MD, Alexandra Hospital, Athens, Greece, explains a phase III study that analyzed pomalidomide in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Jorge E. Cortes, MD, Department of Leukemia, University of Texas, MD Anderson Cancer Center, describes the methods and results of a phase II study examining ponatinib.
The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance—including the stubborn T315I mutation—in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).